Chardan Capital Has Pessimistic View of PRQR FY2024 Earnings

ProQR Therapeutics (NASDAQ:PRQR) – Chardan Capital decreased their FY2024 earnings per share estimates for shares of ProQR Therapeutics in a report released on Sunday, November 10th. Chardan Capital analyst K. Nakae now expects that the biopharmaceutical company will post earnings per share of ($0.31) for the year, down from their previous estimate of ($0.28). The consensus estimate for ProQR Therapeutics’ current full-year earnings is ($0.34) per share. Chardan Capital also issued estimates for ProQR Therapeutics’ FY2025 earnings at ($0.34) EPS.

A number of other brokerages also recently weighed in on PRQR. HC Wainwright increased their price objective on shares of ProQR Therapeutics from $5.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Raymond James raised ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their price target for the company from $6.00 to $14.00 in a report on Tuesday, October 29th. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $7.13.

ProQR Therapeutics Stock Down 0.3 %

Shares of NASDAQ PRQR opened at $3.95 on Wednesday. The firm’s 50-day moving average price is $2.64 and its 200-day moving average price is $2.15. ProQR Therapeutics has a 52-week low of $1.18 and a 52-week high of $4.62. The company has a market cap of $322.64 million, a PE ratio of -12.34 and a beta of 0.26.

Institutional Trading of ProQR Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets grew its position in shares of ProQR Therapeutics by 120.1% during the 1st quarter. BNP Paribas Financial Markets now owns 35,001 shares of the biopharmaceutical company’s stock valued at $80,000 after acquiring an additional 19,100 shares during the period. Acadian Asset Management LLC bought a new position in ProQR Therapeutics in the 1st quarter worth $56,000. EP Wealth Advisors LLC purchased a new position in ProQR Therapeutics during the first quarter valued at $26,000. Ikarian Capital LLC grew its holdings in ProQR Therapeutics by 2.3% during the first quarter. Ikarian Capital LLC now owns 483,583 shares of the biopharmaceutical company’s stock valued at $1,098,000 after purchasing an additional 10,958 shares during the period. Finally, Privium Fund Management B.V. increased its position in ProQR Therapeutics by 4.4% in the second quarter. Privium Fund Management B.V. now owns 5,580,725 shares of the biopharmaceutical company’s stock worth $9,208,000 after buying an additional 236,279 shares in the last quarter. 32.65% of the stock is owned by hedge funds and other institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).